The US FDA has shelved a “Commissioner’s National Priority Voucher” fast-track concept aimed at compressing drug review timelines to roughly one to two months, according to Reuters sources citing internal documents. The voucher program, launched in June 2025, targeted therapies framed as addressing national priorities, including urgent unmet health needs. Critics raised concerns about preferential treatment dynamics tied to political or pricing demands. For biotech sponsors, the move signals potential slowing or policy uncertainty around expedited review mechanisms that had been marketed as timeline predictability tools—an issue that affects launch sequencing, trial planning, and market access budgeting.